Perjeta

Novartis' Afinitor fails frontline breast cancer trial

Afinitor conferred a seven-month improvement in PFS, and while this may warrant further study emerging data for other treatment regimens - such as the combination of Herceptin with Roche's Perjeta

NHS names drugs to be re-evaluated for Cancer Drugs Fund

Kadcyla (trastuzumab emtansine). Breast cancer. Perjeta (pertuzumab). Breast cancer. Sanofi. Jevtana (cabazitaxel).

SMC fails to recommend Roche’s Perjeta

Says drug is not a cost-effective option in breast cancer. The Scottish Medicines Consortium (SMC) has not recommended Roche's Perjeta for use in the treatment of unresectable breast cancer. ... Perjeta demonstrated "phenomenal" results at the European

BMS taps F-star Alpha for immuno-oncology drug

FS102 works differently to current HER2-targeted therapies such as Roche's Herceptin (trastuzumab) and Perjeta (pertuzumab), and is being developed specifically to meet the problem of resistance to those drugs.

Strong sales in breast cancer lift Roche revenues

New products Perjeta and Kadcyla lead growth. Rocketing sales of Roche's new breast cancer drugs Perjeta and Kadcyla suggest they will cushion any impact from biosimilar competition to Herceptin, which ... Last month, Roche reported new clinical data

[ Previous 5 results ] 5 6 7 8 9 10 11 12 13 [ Next 5 results ]